Press releases

Efficacité d’une double approche innovante de thérapie génique dans une maladie neuromusculaire

Press release | 31 Mar 2017 - 15h17 | By INSERM PRESS OFFICE
Genetics, genomics and bioinformatics
TO CITE THIS POST :
Press release – Inserm press room Efficacité d’une double approche innovante de thérapie génique dans une maladie neuromusculaire Link : https://presse.inserm.fr/en/francais-efficacite-dune-double-approche-innovante-de-therapie-genique-dans-une-maladie-neuromusculaire/27979/
Sources

PABPN1 gene therapy for oculopharyngeal muscular dystrophy A. Malerba1,*, P. Klein2,3,*, H. Bachtarzi1,w, S.A. Jarmin1, G. Cordova2,3, A. Ferry2,3, V. Strings4, M. Polay Espinoza2,3, K. Mamchaoui2,3, S.C. Blumen5, J. Lacau St Guily2,3,6, V. Mouly2,3, M. Graham4, G. Butler-Browne2,3, D.A. Suhy4, C. Trollet2,3,* & G. Dickson1,* 1 School of Biological Sciences, Royal Holloway, University of London, Egham Hill, Egham, TW20 0EX Surrey, UK. 2 Sorbonne Universités, UPMC Univ Paris 06, UM76, INSERM U974, Institut de Myologie, CNRS FRE3617, 47 bd de l’Hôpital, 75013 Paris, France. 3 Sorbonne Paris Cité, Université Paris Descartes, 75006 Paris, France. 4 Benitec Biopharma, 3940 Trust Way, Hayward, California 94545, USA. 5 Department of Neurology, Hillel Yaffe Medical Center, Hadera and Rappaport Faculty of Medicine, The Technion, 1 Efron Street, Haifa 31096, Israel. 6 Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and University Pierre-et-Marie-Curie, Paris VI, Tenon Hospital, Assistance Publique des Hôpitaux de Paris, 75252 Paris, France. Nature communications

fermer
fermer
RSS Youtube